cilomilast has been researched along with albuterol in 11 studies
| Studies (cilomilast) | Trials (cilomilast) | Recent Studies (post-2010) (cilomilast) | Studies (albuterol) | Trials (albuterol) | Recent Studies (post-2010) (albuterol) |
|---|---|---|---|---|---|
| 162 | 13 | 42 | 10,108 | 3,059 | 2,058 |
| Protein | Taxonomy | cilomilast (IC50) | albuterol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 1.2618 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Au, BT; Collins, PD; Teixeira, MM; Williams, TJ | 1 |
| Ezeamuzie, CI | 1 |
| Cowley, H; Higgins, R; Kelly, J; Murdoch, RD; Webber, D | 1 |
| Baan, R; Gauw, SA; Grootendorst, DC; Kelly, J; Murdoch, RD; Rabe, KF; Sterk, PJ | 1 |
| Devillier, P | 1 |
| Boetticher, E; Lambertino, A; Learoyd, J; Leff, AR; Meliton, AY; Muñoz, NM; Zhu, X | 1 |
| Aksoy, MO; Ji, R; Kelsen, SG; Li, XX; Reddy, PJ; Yang, Y | 1 |
| Fang, Q; Liu, X; Ma, Y; Michalski, J; Rennard, SI; Wang, J | 1 |
1 review(s) available for cilomilast and albuterol
| Article | Year |
|---|---|
[Physiopathology of COPD: choosing the right therapeutic targets].
Topics: Adrenal Cortex Hormones; Aged; Albuterol; Animals; Bacterial Infections; Bronchodilator Agents; Carboxylic Acids; Cyclohexanecarboxylic Acids; Disease Models, Animal; Drug Therapy, Combination; Humans; Inflammation; Mucociliary Clearance; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Alveoli; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Randomized Controlled Trials as Topic; Rats; Rolipram; Salmeterol Xinafoate; Smoking; Theophylline; Time Factors | 2003 |
2 trial(s) available for cilomilast and albuterol
| Article | Year |
|---|---|
Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Albuterol; Blood Pressure; Bronchodilator Agents; Carboxylic Acids; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Interactions; Electrocardiography, Ambulatory; Heart Rate; Humans; Male; Middle Aged; Nitriles; Time Factors | 2002 |
Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Albuterol; Analysis of Variance; Area Under Curve; Bronchodilator Agents; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ipratropium; Male; Maximal Expiratory Flow Rate; Middle Aged; Nitriles; Pulmonary Disease, Chronic Obstructive | 2003 |
8 other study(ies) available for cilomilast and albuterol
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Albuterol; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Drug Synergism; Humans; Interleukin-8; Neutrophils; Nitriles; Phosphodiesterase Inhibitors; Prostaglandins; Pyridines; Pyrrolidinones; Rolipram; Zymosan | 1998 |
Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenylyl Cyclases; Adult; Albuterol; Benzamides; Cell Degranulation; Colforsin; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Dinoprostone; Dose-Response Relationship, Drug; Enzyme Activation; Eosinophil Peroxidase; Eosinophils; Histamine; Humans; Nitriles; Peroxidases; Phosphodiesterase Inhibitors; Pyridines; Rolipram; Superoxides; Theophylline | 2001 |
Phosphodiesterase 4 inhibition of beta2-integrin adhesion caused by leukotriene B4 and TNF-alpha in human neutrophils.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Adult; Albuterol; Carboxylic Acids; CD11b Antigen; CD18 Antigens; Cell Adhesion; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Extracellular Signal-Regulated MAP Kinases; Humans; Leukotriene B4; Middle Aged; Neutrophils; Nitriles; Phosphodiesterase Inhibitors; Salmeterol Xinafoate; Signal Transduction; Tumor Necrosis Factor-alpha; Up-Regulation | 2006 |
Inhibition by salmeterol and cilomilast of fluticasone-enhanced IP-10 release in airway epithelial cells.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Carboxylic Acids; Cells, Cultured; Chemokine CXCL10; Cyclohexanecarboxylic Acids; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Gene Expression; Humans; Interleukin-8; Nitriles; Phosphodiesterase Inhibitors; Respiratory Mucosa; Reverse Transcriptase Polymerase Chain Reaction; RNA; Salmeterol Xinafoate | 2008 |
PGE 2 desensitizes β -agonist effect on human lung fibroblast-mediated collagen gel contraction through upregulating PDE4.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Collagen; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Dinoprostone; Fibroblasts; Gels; Gene Expression Regulation; Humans; Indomethacin; Lung; Nitriles; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate; Up-Regulation | 2013 |